Navigation Links
Microarray technology for tailoring breast cancer therapy

Microarray technology could be used to tailor therapy according to the individual, and prevent breast cancer patients from having to undergo painful unsuccessful therapies. In a study published in the journal Breast Cancer Research, researchers analysed tumour tissue samples and identified a group of64 genes that can be used to predict a patient's response in the five years after adjuvant therapy for breast cancer. Identifying patients whose breast tumours express these genes could potentially be used to predict which patients would not benefit from adjuvant therapy, and avoid patients being given therapies with the potential of causing more harm than good.

A team of researchers led by Jonas Bergh from the Karolinska Institutet in Stockholm, Sweden, analysed the gene expression profiles of 159 breast cancer patients using DNA microarray analysis. From these samples they identified the genetic signatures shown by 38 patients who had a poor prognosis - defined as relapse or death from any cause within 5 years. The remaining 121 patients were defined as the 'good prognosis' group. The researchers also used gene expression profiling to separate patients who did well with and without adjuvant therapy, and those whose tumours failed to respond to treatment.

An analysis of the genes expressed in the tumours of all 159 patients showed that 64 genes were used to separate the patients with good and poor prognoses.The researchers then tested the predictive value of the group of 64 genes compared with three currently used clinical markers. Using the expression patterns of the 64 genes identified by the researchers gave significantly better(P=0.007) prediction rates than histological grading, tumour stage and age - which are all accepted prognostic markers for breast cancer.

The present lack of criteria to help tailor breast cancer treatment to individual patients indicates a need to develop new techniques for better prediction of how patients will respond
'"/>

Source:Karolinska Institutet


Page: 1 2

Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
3. Breakthrough Microarray-based Technology for the Study of Cancer
4. Nanogen Issued Patent for Electronic Microarray With Memory
5. Characterizing Skin Cancer by Microarrays
6. Microarrays as phenotype
7. $6.5 Million Grant for Microarray Center at Yale School of Medicine
8. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
9. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
10. Novel technology detects human DNA mutations
11. Novel antiviral technology inhibits RSV infection in mice

Post Your Comments:
(Date:11/4/2009).... 20 Aware, Inc. (Nasdaq...ogy and biometrics software, today reported financ... 30, 2009. ,, Michael Tzannes, Aware,s Chairm...ay, we announced an agreement to sell our DSL and ...less semiconductor company being spun out of Infin...
(Date:11/4/2009)...PRNewswire/ -- Global Rainmakers, Inc., an intelle...D laboratory, today announced that the company has...vely commercialize its suite of technologies desig...ferings. ,, During the past four years, the com...lop and deploy a series of core--but expandable--t...
(Date:11/3/2009)...4, 2009 -- The world,s greatest wines are the res...man input, and something called the "terroir" -- a...d climate. , Experts will discuss terroir with...nesday, Nov. 4 in Pittsburgh. "Terroir: Winegrape...rts at the 2009 Annual Meetings of the American So...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Great wines come from great soils 2Polaroid 28R 29 and The Breast Cancer Research Foundation 28R 29 Print Pink 58554 1Polaroid 28R 29 and The Breast Cancer Research Foundation 28R 29 Print Pink 58554 2Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 1Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 2Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 3Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 4Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 5Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 1Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 2Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 3Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 4Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 5
...egulates blood pressure in response to daily stres...ople whose pressure is out of control. , "Resear...ressure is not controlled despite the best efforts...gory Harshfield, director of the Georgia Preventio..."We are trying to identify the mechanisms through ...
...es in the Amazon will survive even grim scenarios ... could suffer extinction rates of up to 50 percent... the Aug. 12 issue of the journal Proceedings of ...ill natural systems prove to be as they weather th...obal change? The debate is on between proponents o...
... bloodhound, Sentry the newest in an elite group ...own in demanding and rugged environments has help...bservation sites of a pioneering seafloor laborato...ccessful selection of the two sites is a crucial s...e and below the seafloor on the Juan de Fuca Plate...
Other Biology News:Blood pressure response to daily stress provides clues for better hypertension treatment 2Blood pressure response to daily stress provides clues for better hypertension treatment 3Blood pressure response to daily stress provides clues for better hypertension treatment 4Blood pressure response to daily stress provides clues for better hypertension treatment 5Blood pressure response to daily stress provides clues for better hypertension treatment 6Extinction most likely for rare trees in the Amazon rainforest 2New robot scouts best locations for components of undersea lab 2New robot scouts best locations for components of undersea lab 3
(Date:11/6/2009)...Newswire/ -- Calbiotech, Inc. announced today that...esearch (SBIR) Phase I contract by the U.S. Army M...of the agreement, Calbiotech will develop analyte ...ue virus. ,, Dengue virus is a mosquito-born...tary forces deployed to tropical areas of the worl...
(Date:11/5/2009)...wire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) t... quarter ended September 30, 2009. GenVec reported...the three months ended September 30, 2009 compared...n the comparable quarter of 2008. For the nine mon...s $14.1 million ($0.15 per share), compared to a n...
(Date:11/5/2009)...mber 5, 2009 at 4:30 p.m. Eastern Time , BOTH.../ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" o...naudited financial results for the third quarter a...ed the Company,s highlights for the third quarter ...reflect the operations of OncoGenex Technologies I...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: S...e receptor-based technologies to discover novel fl...dient supply industries, today provided a corporat...ird quarter ended September 30, 2009. Revenues we...pared to $4.0 million for the third quarter of 200...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...Oct. 29 Aloka Co., Ltd., the Innovator in,Ultraso...troduction of two,ultrasound systems with dedicate...ing, the ProSound Alpha 10 and the ProSound Alpha ...ociation, at the Orange County,Convention Center i...und Alpha 7 and the Alpha 10 incorporate all of th...
...s Presented at American Academy of Pediatrics Nati...hibition, SAN FRANCISCO and EAST NORRITON, Pa., O...icine, announced today that findings from,a precli...Academy of,Pediatrics (AAP) National Conference an...n Neo-Bladder Augment(TM) to restore bladder funct...
...K, October 29 XTL Biopharmaceuticals,Ltd. (NASDAQ...t Ron Bentsur,the Company,s Chief Executive Office...dman & Renshaw 9th Annual Health Care Conference. ...y including a discussion of,Bicifadine, the Compan... of,neuropathic pain. Mr. Bentsur,s presentation w...
Other Biology Technology:ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 3Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 2Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 3XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference 2
...500-MS LC Ion Trap is the instrument of choice for... reliability and productivity are essential.,...demanding LC/MS/MS applications. The system sensit...58;ect the ion trap technologys inherent advantage...
Benchtop Ductless Exhaust Fume Hood from Terra Universal, Inc.
Distillation Hood from Terra Universal, Inc.
Telomerase Gel-based assay Assay Kit, TRAPeze from CHEMICON
Biology Products: